Background. Acute viral gastroenteritis is one of the leading causes of diarrheal diseases. The FilmArray GI Panel is a PCR based assay that detects 22 different enteric pathogens including five viruses (Adenovirus F 40/41, Astrovirus, Norovirus GI/GII, Rotavirus A, and Sapovirus (I, II, IV, and V)) in an hour. The epidemiology and management of acute viral gastroenteritis is described.
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Methods. Children with acute gastroenteritis were prospectively enrolled at emergency departments of five geographically different pediatric facilities during [2015] [2016] . Stool specimens were collected and tested by the FilmArray GI Panel.
Results. A total of 1157 subjects were enrolled in the study. Stool specimens from 961 subjects were collected. Subjects with viral, bacterial, and parasitic etiology as identified by the FilmArray GI Panel were 429 (44.6%), 392 (40.8%), and 41 (4.3%), respectively. Viral AGE was common in winter months from October through March (274/429; 63.9%); norovirus was the leading viral agent (205/429; 47.8%) and was more commonly detected in winter months (147/205; 71.7% Background. Clostridium difficile (Cd) infections rates and severity have been related to the emergence and spread of a hypervirulent toxigenic strain B1/NAP1/027. This strain has been related to outbreaks in North America and Europe, and most recently in Latin America. Our objective was to describe the prevalence of Cd strain BI/NAP1/027 among patients in Terciary care hospital in Cali-Colombia.
Methods. Between January 2012 and May 2016 patients with Hospital acquiere diarrhea were screen for Cd. Molecular diagnosis of Cd strains was done through realtime polymerase chain reaction by detecting the toxin B gen, binary toxin gen and tcdC 117 nucleotide (GeneXpert; Cepheid, Sunnyvale, CA, USA).
Results. A total of 337 adult patients were studied. Median age was 61 years (25-87). Women accounted for 57.2%. The diagnosis of C. difficile was done in 48 patients (12.2%), of them 14 tested positive for the BI/NAP1/027 strain (29.2%). 92% of the cases scored severely. Two patients died due to Cd 027 strain infection (14.3%).
Conclusion. Although the proportion of patients with C. difficile was low, almost one-third of them tested positive for BI/NAP1/027 strain. Emerging prevalence of Hypervirulent strains could be a major threat in Latin America, Disclosures. All authors: No reported disclosures. Background. Acute infectious diarrhea is a leading cause of hospitalizations, outpatient visits, and lost quality of life in the United States. Rapid diagnostic technology may provide an opportunity to quickly optimize ABX therapy for acute infectious diarrhea. The GIP is a multiplex PCR test that detects 13 bacteria, 5 viruses, and 4 parasites in approximately 1 hour of run time. Our objective was to determine the frequency of alterations in empiric ABX therapy for acute diarrhea within 48 hours of reporting of GIP results.
Utilization of FilmArray Gastrointestinal Panel (GIP) Results on Altering Empiric Antibiotic (ABX) Use in Patients with
Methods. Patients that had the GIP performed on diarrheagenic stool while in our emergency department or an inpatient location from January 1 to June 30, 2016 were identified. Patient data, including gender, race, age, ABX use and duration, and the results of non-stool bacterial cultures (if obtained) were collated with GIP results.
Results. Complete patient information and GIP results were available on 517 patients. At least 1 positive result occurred in 220 patients; 45 patients (8.7%) had ≥ 2 positive results. There were 161, 73, and 2 positive results for bacteria, viruses, and parasites, respectively. Clostridium difficile (n = 99) was most commonly identified and it was the only organism identified in 80 patients. Within 48 hours of result availability in the medical record, ABX were added in 47.3% of patients with any positive result and 24.2% of patients with negative results. Empiric ABX were stopped in 42.9 and 48.6% of patients with positive or negative results, respectively. ABX were altered (ie, start, stop, dose change) in 55.9 and 38.4% of patients with positive or negative results, respectively.
Conclusion. GIP results appear to impact changes in ABX therapy, though these may not have been the sole driver of change in all cases. That there may be room for improvement suggests an opportunity for antimicrobial stewardship (AST) initiatives, such as prospective auditing of GIP results by AST staff who make recommendations to the treatment team, or an expansion of our current gastroenteritis guidelines to include a clinical pathway for all organisms on the GIP to decrease inappropriate ABX use.
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